WOBURN, Mass., Oct. 27, 2023 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of interventional treatment solutions, announced today the commercial availability of the LAVA® Liquid ...
WOBURN, Mass., April 19, 2021 /PRNewswire/ -- Sirtex Medical (Sirtex), a leading manufacturer of targeted liver cancer therapies, and BlackSwan Vascular, Inc. (BlackSwan), a Bay Area-based private ...
Sirtex, a global healthcare business, unveils first-of-its-kind product to treat peripheral vascular haemorrhage. LAVA provides volume and viscosity options that optimize the flexibility needed to ...
WOBURN, Mass., Dec. 9, 2020 /CNW/ -- Sirtex Medical (Sirtex), a leading manufacturer of targeted liver cancer therapies, announced a strategic investment in BlackSwan Vascular, Inc. (BlackSwan), a Bay ...
LAVA clinical trial underway for potential first FDA-approved liquid embolic system for a peripheral vascular indication WOBURN, Mass., April 19, 2021 /PRNewswire/ -- Sirtex Medical (Sirtex), a ...
WOBURN, Mass., April 19, 2021 /PRNewswire/ -- Sirtex Medical (Sirtex), a leading manufacturer of targeted liver cancer therapies, and BlackSwan Vascular, Inc. (BlackSwan), a Bay Area-based private ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results